Core Viewpoint - The stock of Bolekang Vision Cloud-B (2592.HK) has surged over 11%, marking a total increase of over 70% in the past six days, with the share price surpassing 8 HKD and a market capitalization of 6.824 billion HKD [1] Group 1 - Bolekang Vision Cloud-B announced the acquisition of two patents in Japan and Europe for its core product CBT-009, which is aimed at delaying myopia and treating eye diseases [1] - The company is expected to collaborate with major pharmaceutical firms to establish licensing arrangements for the production, development, and distribution of CBT-009 in Japan and Europe, which are key high-end markets for the product [1] - These collaborations and licensing arrangements are anticipated to enhance and accelerate the global commercialization potential of CBT-009 [1]
港股异动丨拨康视云-B续涨超11% 近6日连涨超70% 获日本及欧洲两项专利